In addition, multiple studies have shown that patients with FSGS were reclassified as Alport syndrome based on mutations found in COL4A3, COL4A4, and COL4A5 (Adam et al., 2014; Gast et al., 2016; Yao et al., 2019). Here, COL4A3 is linked to focal segmental glomerulosclerosis.